Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injec

-- First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants ---- Mean Estimated Elimination Half-Life for RLYB116 was > 300 Hours ---- No Severe or Seriou...

Related Keywords

New Haven ,Connecticut ,United States ,United Kingdom ,Jorge Gaeta ,Eric Watsky ,Hannah Deresiewicz ,International Complement Workshop ,Linkedin ,Exchange Commission ,Twitter ,Rallybio Corporation Nasdaq ,Stern Investor Relations Inc ,Dose Administration ,In Human Single Ascending Dose Clinical Data ,Estimated Elimination Half Life ,Serious Adverse Events ,Single Dose Administration ,Ascending Dose Study ,Preliminary Safety ,Rallybio Corporation ,Technology Incubation Program ,Quarterly Report ,Investor Relations ,